yeztugo hiv - Search News

News

HIV, CVS Health and Gilead Sciences

For now, CVS declines to cover Gilead's long-acting HIV PrEP treatment Yeztugo

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV prevention breakthrough, at least for now. | CVS Health, the parent of PBM juggernaut CVS Caremark,

· 1d · on MSN

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.

· 1d · on MSN

Exclusive: CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists

STAT2d

Pharmalittle: We’re reading about Gilead’s HIV drug, FDA speeding review of a rare disease drug, and more

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

The Herald on MSN11d

Yeztugo: Life-saving HIV prevention injection costs $28,000 a year

Gilead Sciences has secured approval from the United States health authorities for its new HIV prevention injection, Yeztugo, but concerns are growing over its steep price tag.

Seeking Alpha1mon

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for ...

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025 Jul. 14, 2025 9:30 AM ET Gilead Sciences, Inc. (GILD) ...

GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results